CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

As of and for the Year Ended September 30, 2024 (With Summarized Comparative Totals for 2023)

And Report of Independent Auditor



TABLE OF CONTENTS

REPORT OF INDEPENDENT AUDITOR	1-3
CONSOLIDATED FINANCIAL STATEMENTS	
Consolidated Statement of Financial Position	4
Consolidated Statement of Activities	5
Consolidated Statement of Cash Flows	6
Notes to the Consolidated Financial Statements	7-18
SUPPLEMENTARY INFORMATION	
Schedule of Expenditures of Federal Awards	19
Notes to the Schedule of Expenditures of Federal Awards	20
COMPLIANCE SECTION	
Report of Independent Auditor on Internal Control over Financial Reporting and on	
Compliance and Other Matters Based on an Audit of Financial Statements	
Performed in Accordance with Government Auditing Standards	21-22
Report of Independent Auditor on Compliance for Each Major Federal Program and on	
Internal Control over Compliance Required by the Uniform Guidance	23-24
Schedule of Findings and Questioned Costs	



Report of Independent Auditor

To the Board of Directors United Network for Organ Sharing and Subsidiary Richmond, Virginia

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of United Network for Organ Sharing and Subsidiary (UNOS - a nonprofit organization) (the "Organization"), which comprise the consolidated statement of financial position as of September 30, 2024, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Organization as of September 30, 2024, and the changes in their net assets and their cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the consolidated financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

1

In performing an audit in accordance with generally accepted auditing standards and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
 financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the Organization's 2023 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated January 18, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended September 30, 2023, is consistent, in all material respects, with the audited financial statements from which is has been derived.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards, as required by Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated February 19, 2025, on our consideration of the Organization's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control over financial reporting and compliance.

Richmond, Virginia February 19, 2025

Cherry Bekaert LLP

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

	2024	2023
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 9,927,974	\$ 21,093,189
Restricted cash	6,317,018	16,126,990
Investments	20,490,404	16,530,847
Restricted investments	20,026,465	15,620,099
Accounts receivable, net	28,258,207	12,185,595
Prepaid expenses	3,876,627	4,162,564
Total Current Assets	88,896,695	85,719,284
Property and equipment, net	18,641,363	19,595,409
Other assets	479,359	489,934
Total Assets	\$ 108,017,417	\$ 105,804,627
LIABILITIES AND NET ASSETS		
Current Liabilities:		
Current maturities of bonds payable	\$ 690,000	\$ 670,000
Accounts payable and accrued expenses	8,495,859	9,235,288
Health insurance liability	1,473,318	1,516,349
Deferred revenue	373,212	394,056
Due to National Organ Procurement Transplantation Network	 33,991,225	 26,847,958
Total Current Liabilities	45,023,614	 38,663,651
Long-Term Liabilities:		
Bonds payable, less current portion	1,455,000	2,145,000
Total Liabilities	 46,478,614	 40,808,651
Net Assets:		
Without donor restrictions	60,716,035	63,995,828
With donor restrictions	 822,768	 1,000,148
Total Net Assets	61,538,803	 64,995,976
Total Liabilities and Net Assets	\$ 108,017,417	\$ 105,804,627

CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

	OPTN	Network and Member Services	Management and General	Fundraising	2024 Total	2023 Total
Change in Net Assets Without Donor Restrictions: Revenues and Other Support:						
OPTN registration fees	\$ 69,078,490	\$ -	\$ -	\$ -	\$ 69,078,490	\$ 71.805.579
Government contract - OPTN	6,441,705	-	-	-	6,441,705	6,500,000
UNOS fees	-	9,600,786	-	_	9,600,786	6,619,800
Contributions	-	-	-	280,592	280,592	514,078
Scientific and data analysis services	-	2,132,220	-	-	2,132,220	1,936,784
Regional and transplant forums	-	44,731	-	93,874	138,605	99,300
Miscellaneous	-	7,223,325	-	-	7,223,325	1,621,007
Satisfaction of program restrictions		478,389			478,389	587,092
Total Revenues and Other Support	\$ 75,520,195	\$ 19,479,451	\$ -	\$ 374,466	95,374,112	\$ 89,683,640
Expenses:						
Salaries	\$ 29,222,173	\$ 8,825,789	\$ 6,115,388	\$ 543,869	44,707,219	41,785,015
Employee benefits and payroll taxes	14,170,491	4,060,536	2,206,502	181,273	20,618,802	18,887,064
Temporary help	618,752	110,865	-	1,110	730,727	617,635
Meetings and travel	2,591,706	1,473,861	126,692	29,641	4,221,900	4,479,689
Professional education programs and projects	14,813	-	-	-	14,813	6,827
Other purchased services	11,124,783	6,307,686	1,501,789	3,413	18,937,671	14,896,880
Telephone, telecommunications, and utilities	-	60,573	343,340	-	403,913	463,093
Equipment leases	-	-	107,570	-	107,570	113,857
Subscriptions and software	5,750,956	668,995	-	-	6,419,951	5,197,345
Repairs and maintenance	1,001,337	111,152	371,300	-	1,483,789	1,751,855
Depreciation and amortization	1,125,840	-	957,285	-	2,083,125	2,194,642
Indirect costs and benefit adjustment	9,437,456	-	(9,437,456)	-	-	-
Other	461,888	1,321,238	1,646,568	54,746	3,484,440	3,287,183
Total Expenses	\$ 75,520,195	\$ 22,940,695	\$ 3,938,978	\$ 814,052	103,213,920	93,681,085
Revenues (under) over Expenses					(7,839,808)	(3,997,445)
Investment return, net					4,483,141	2,165,628
Unrealized gain on insurance					76,874	5,320
Loss on disposal of property and equipment						(25,724)
Change in Net Assets Without Donor Restrictions					(3,279,793)	(1,852,221)
Change in Net Assets With Donor Restrictions:						
Contributions Net assets released from restrictions					301,009 (478,389)	1,310,850 (587,092)
Change in Net Assets With Donor Restrictions					(177,380)	723,758
Change in net assets					(3,457,173)	(1,128,463)
Net assets, beginning of year					64,995,976	66,124,439
Net assets, end of the year					\$ 61,538,803	\$ 64,995,976

CONSOLIDATED STATEMENT OF CASH FLOWS

YEAR ENDED SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

		2024	2023
Cash flows from operating activities:			
Change in net assets	\$	(3,457,173)	\$ (1,128,463)
Adjustments to reconcile changes in net assets to net cash			
flows from operating activities:			
Depreciation and amortization		2,083,125	2,194,642
Bad debt expense		48,916	62,576
Loss on disposal of property and equipment		-	25,724
Gain on insurance values		(76,874)	(5,320)
Realized and unrealized gain on investments, net		(3,593,685)	(1,839,939)
Change in operating assets and liabilities:			
Accounts receivable		(16,121,528)	(1,025,115)
Prepaid expenses		285,937	116,002
Other assets		87,450	104,727
Accounts payable and accrued expenses		(739,429)	4,425,951
Health insurance liability		(43,031)	406,937
Deferred revenue		(20,844)	-
Due to National Organ Procurement Transplantation Network		3,394,822	 (14,061,991)
Net cash flows from operating activities		(18,152,314)	 (10,724,269)
Cash flows from investing activities:			
Purchases of property and equipment		(1,129,080)	(483,168)
Proceeds from the sale of Investments		-	1,624,753
Purchases of investments		(1,023,793)	(1,557,947)
Net cash flows from investing activities		(2,152,873)	 (416,362)
Cash flows from financing activities:			
Repayments of bonds and notes payables		(670,000)	 (645,000)
Net cash flows from financing activities		(670,000)	 (645,000)
Change in cash, cash equivalents, and restricted cash		(20,975,187)	(11,785,631)
Cash, cash equivalents, and restricted cash, beginning of year		37,220,179	 49,005,810
Cash, cash equivalents, and restricted cash, end of year	\$	16,244,992	\$ 37,220,179
Supplemental disclosures of cash flow information:			
Cash paid during the year for interest	\$	108,671	\$ 173,636
Cash paid during the year for income taxes		20,264	\$ 3,365
Supplemental disclosures of noncash investing activities:			
Appreciation on restricted investments due to OPTN	\$	(3,748,445)	\$ (1,682,346)
Supplemental disclosures - cash, cash equivalents, and restricted cash:	:		
Cash and cash equivalents	\$	9,927,974	\$ 21,093,189
Restricted cash		6,317,018	16,126,990
Cash, cash equivalents, and restricted cash, end of year	\$	16,244,992	\$ 37,220,179

The accompanying notes to the consolidated financial statements are an integral part of these statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 1—Organization and nature of operations

United Network for Organ Sharing and Subsidiary ("UNOS" or the "Organization"), a Virginia non-stock, not-for-profit corporation, operates the National Organ Procurement and Transplantation Network ("OPTN") established by the National Organ Transplantation Act passed by the U.S. Congress in 1984. Through a contract with the Health Resources and Services Administration ("HRSA") of the Department of Health and Human Services ("DHHS") (the "OPTN Contract"), the Organization functions as the sole national network whose mission is to improve the effectiveness of the United States organ procurement and transplantation system and to provide for the fair and equitable distribution of all donated organs. To carry out this mission, the Organization maintains a computerized database to identify potential transplant recipients and to provide for the systematic matching of donated organs with such recipients. The Organization is staffed 24 hours a day, 7 days a week, with specialists trained in assisting transplant centers and in administering Board of Directors-approved organ allocation policies. All organ procurement organizations and transplant facilities in the United States are required to be members of OPTN. The Organization's Board of Directors is split between OPTN and UNOS. The OPTN Board is currently made up of 47 voting members elected from the Organization's membership and the general public. The UNOS Board is currently made up of seven voting members.

On September 12, 2013, the Organization was awarded an OPTN Contract from HRSA for the period September 30, 2013 through September 29, 2014, with additional one-year options to extend the OPTN Contract to September 29, 2015, 2016, 2017, and 2018, and a six-month option to extend the OPTN Contract from October 1, 2018 through March 31, 2019. On November 3, 2018, the Organization was awarded the latest OPTN Contract from HRSA for the period April 1, 2019 through September 29, 2019, with additional one-year options to extend the OPTN Contract to September 29, 2020, 2021, 2022, and 2023.

During fiscal year 2023, HRSA exercised its unilateral right to extend the contract for an additional six months, through March 2024, with four twelve-month extension options following the six-month extension. The base extension ended December 29, 2024, and there are two option periods. The OPTN Contract is the primary source of revenue for the Organization. If the Organization is not awarded the OPTN Contract extensions, its future operations would be materially and adversely affected.

On August 3, 2023, the Organization established Chorus, LLC ("Chorus"), a wholly-owned subsidiary located in Richmond, Virginia. Chorus was organized under Section 501(c)(3) of the Internal Revenue Code of 1986 and its purpose is to operate exclusively for charitable, scientific, and educational purposes.

Note 2—Summary of significant accounting policies

Basis of Accounting – The accompanying consolidated financial statements of the Organization have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Basis of Presentation – The consolidated financial statements include certain prior year summarized comparative information in total but not by functional category. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the consolidated financial statements as of and for the year ended September 30, 2024, from which the summarized information was derived.

Principles of Consolidation – The consolidated financial statements include the accounts of Chorus. All significant intercompany accounts and transactions have been eliminated in consolidation.

Functional Allocation of Expenses – The costs of providing the various programs and other activities have been summarized by natural classification on a functional basis in the accompanying statement of activities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 2—Summary of significant accounting policies (continued)

Costs that are billed under the provisions of the OPTN Contract are reflected as costs of the program. Network and member services include items such as educational initiatives to increase organ donation and other non-contract expenses.

Certain categories of expenses are attributable to more than one program or supporting service function and are allocated on a reasonable basis that is consistently applied through judgement and estimation.

The major expense categories include the following:

Expense

Salaries and benefits Information technology Other purchased services

Depreciation

Repairs and maintenance

Method of Allocation

Time and effort Specific use Direct expense

Useful life and contract language

Direct expense

Use of Estimates – The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates.

Net Assets - The Organization's net assets, revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Organization are classified and reported as follows:

Without Donor Restrictions - Net assets that are not subject to donor-imposed stipulations. Net assets without donor restrictions that may be designated for specific purposes by action of the Board of Directors or may otherwise be limited by contractual agreements with outside parties.

With Donor Restrictions – Net assets whose use by the Organization is subject to donor-imposed stipulations. Some donor-imposed stipulations are temporary in nature and can be fulfilled by actions of the Organization pursuant to those stipulations or expire by the passage of time. Other donor-imposed restrictions are perpetual in nature and should be maintained in perpetuity by the Organization. At September 30, 2024 and 2023, the Organization held \$657,920 and \$-0- in perpetuity, respectively.

Cash and Cash Equivalents – Cash and cash equivalents include cash on hand, cash in banks, and highly liquid cash management funds with an original maturity of three months or less.

Restricted Cash and Investments - Restricted cash and investments represent those funds that have been collected from OPTN members on behalf of the OPTN, for which cost reimbursement vouchers have not been submitted to the DHHS, or contributions received subject to donor-imposed stipulations.

Concentrations of Credit Risk - The Organization places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation provides insurance coverage up to \$250,000 for substantially all depository accounts. The Organization from time to time may have amounts on deposit in excess of the insured limits. As of September 30, 2024 and 2023, the Organization had \$16,047,254 and \$36,977,554, respectively, in deposits that exceeded these insured amounts.

Historically, the Organization has not experienced significant losses related to accounts receivable and, therefore, believes that the credit risk related to accounts receivable is minimal.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 2—Summary of significant accounting policies (continued)

The Organization derived approximately 79% and 86% of its revenue without donor restrictions from government contracts for the years ended September 30, 2024 and 2023, respectively.

Investments – The Organization accounts for investments in accordance with Financial Accounting Standards Board ("FASB") guidance on accounting for investments held by not-for-profit organizations. The guidance requires certain investments to be reflected at fair value in the statement of financial position. The fair value of investments is determined by an independent market valuation service using quoted closing prices at the end of the period. Interest income and dividends are recorded on the accrual basis. Investments are exposed to various risks, such as interest rate, market, and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in the risks in the near term could materially affect amounts reported in the consolidated financial statements.

Property and Equipment – Property and equipment are carried at historical cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the assets estimated useful lives of 39 years for the building, 3 to 15 years for furniture and non-computer equipment, and 3 to 5 years for computer equipment. Expenditures of less than \$5,000 for property and equipment are expensed as incurred. The cost and accumulated depreciation applicable to assets retired or sold are removed from the respective accounts, and gains or losses thereon are included in changes in net assets.

The carrying value of property and equipment is evaluated when certain events or changes in circumstances indicate that the carrying amount may exceed fair value. Fair value is calculated by estimating cash flows produced by the assets over their remaining useful lives. If undiscounted projected cash flows are less than the carrying amount, an impairment would be recognized. No impairments were identified during 2024.

Income Taxes – The Organization has been granted an exemption from federal income taxes under Internal Revenue Code Section 501(c)(3) except for income generated from unrelated business activities. Unrelated business activities include rental income on debt financed property and travel agency services. Income tax benefit on losses from these activities was \$20,264 and \$3,365 for the years ended September 30, 2024 and 2023, respectively. The Organization's tax returns are generally subject to examination for three years after the later of the due date or date of filing.

Due to OPTN – Due to OPTN represents total OPTN registrations billed to OPTN members, less OPTN registration funding claimed by the Organization on the OPTN vouchers submitted to DHHS.

Compensated Absences – The Organization accrues a provision for vacation and holiday pay due to employees, which is reflected in accounts payable and accrued expenses on the statement of financial position.

Donated Services – The Organization recognizes donated services as contributions in accordance with guidance issued by FASB. Under this guidance, such services are recorded if the services create or enhance nonfinancial assets or require specialized skills, are performed by people with those skills, and would otherwise be purchased by the Organization.

Gifts-In-Kind – Gifts-in-kind revenue is recognized in accordance with FASB Accounting Standards Codification ("ASC") 958-605. In circumstances in which the Organization distributes gifts-in-kind as part of its programs, it reports an expense which is reported in the functional classification for the program in which the gifts-in-kind were used. The Organization did not receive gifts-in-kind contributions of goods used for special events for the years ended September 30, 2024 or 2023.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 2—Summary of significant accounting policies (continued)

Health Insurance – In January 2018, the Organization switched from a fully-insured health insurance plan for employees to a self-funded plan. There is no limit per claim on the Organization's self-insured health insurance. The specific stop loss limit as of September 30, 2024 and 2023 is \$150,000. The estimated liability as of September 30, 2024 and 2023 is \$1,473,318 and \$1,516,349 respectively, and is reported as health insurance liability in the accompanying consolidated statement of financial position.

Revenue Recognition – The Organization recognizes revenue in accordance with FASB ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 established principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The Organization recognizes revenue from contracts as services are provided, which corresponds to the year in which the performance obligations for services are rendered (see Note 3).

Adopted Accounting Pronouncements – As of October 1, 2023, the Organization adopted the provisions of FASB ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) and subsequently related amendments (ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11, and ASU 2022-02). This guidance replaces the existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost based on expected credit losses. The estimate of expected credit losses requires the incorporation of historical information, current conditions, and reasonable and supportable forecasts. There was no material impact on the consolidated financial statements as a result of this adoption.

Note 3—Revenue recognition

The Organization oversees the OPTN as their primary source of revenue. Related revenue directly related to administering the OPTN accounts for over 79% of the total revenue for the year ended September 30, 2024 which includes the OPTN Patient Registration Fees, Government appropriated funds, and UNOS Fees. Other revenue streams include scientific and data services, grants, and educational forums which are a direct result of the Organization's role in being the OPTN contractor. Items such as contributions are strictly an UNOS engagement, as soliciting contributions are excluded from the OPTN Contract.

The Organization's revenue streams consist of the following:

OPTN Registration Fees – The Organization provides services under a contract with the Department of Health and Human Services (HHS). Under this contract the Organization bills member organizations monthly based on data obtained from the Organization's registration system for all registrations added in the previous month at the federally approved fee. This fee is collected on behalf of the OPTN. Each month the Organization submits a monthly voucher that details all of the direct and indirect costs incurred in carrying out the contract, which is approved by HHS. Services provided under this contract are considered to be a series of distinct services that are accounted for as a single performance obligation since each performance obligation is satisfied over time and the Organization uses the same method in measuring progress towards satisfaction of the contract. The transaction price is set each year and ultimately approved by the Secretary of HHS. Indirect rates are billed based on provisional rates which are trued up upon receipt of approved final rates. During 2024, the Organization recorded an indirect rate adjustment related to the years ended September 30, 2024 and 2023 in the amount of \$391,132 and \$2,429,272, respectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 3—Revenue recognition (continued)

UNOS Fees – The UNOS fee is a monthly charge based on additional work to include analysis and data related services provided to all transplant community members that the Organization bills to those same member organizations that received an OPTN fee and is solely a UNOS based fee. Transplant community members who register patients each month receive a UNOS fee invoice that aligns with the number of registrations from the prior month, similar in timing to the OPTN billing practice. UNOS fee revenue is recognized immediately as revenue as all of the services have been provided at the time of billing. The transaction price for the UNOS fee is set each year and ultimately approved by the UNOS Board of Directors. Revenue from each UNOS fee is recognized at a point in time because the customer benefits from and consumes the services immediately. UNOS fee revenue is a single performance obligation that is a series of individually distinct goods or services.

Government Contract — As a result of this contract being a cost reimbursement contract, monthly costs are compiled together to create an invoice to the federal government. Costs incurred under the provisions of the contract are reflected as costs of the program. Under this contract, the government pays the amount based on a floating cost sharing agreement, equivalent to approximately between 10% and 11% of total contract expense, and the remainder is paid through collected organ listing registration fees that are drawn out of the OPTN bank account, which is managed and collected by the Organization on behalf of OPTN. The annual amount of revenue can be split into two categories. In the first category of revenue, the fixed amount of revenue from the federal government is part of the formal federal government. The fiscal year budget is negotiated and agreed to at the execution of the 5-year OPTN Contract. Revenue is recognized over the life of the contract as the Organization performs the required monthly services. In the second category of revenue, HRSA has the option to request and execute optional tasks under the contract, which is also negotiated at the execution of the 5-year OPTN Contract. The contract specifies that based on the estimated size of the work, a specific revenue amount has been previously calculated. Revenue is recognized over time as services are performed under the contract.

Scientific and Data Analysis Services – Individual contracts between the Organization and other organizations for a variety of work including collaborative registries, post-market study registries, research consulting, logistics, transplant analytics, and scientific data and analysis. Each hour is distinct, and revenue is recognized over time and substantially the same with the same pattern of transfer. Services provided by each hourly contract employee is a single performance obligation that is a series of individually distinct goods or services. The Organization charges up-front fees for development costs. Revenue is recognized over the life of the contract. Contracts are billed according to the agreement in each contract.

Miscellaneous Revenue – Other services that may be subject to unrelated business income tax as non-mission focused services and are recognized as revenue as the service is rendered.

Contributions revenue with donor restrictions represents funds received through a gift or grant that are restricted by the donor to be expended for a specific purpose and are recognized as revenue when received. The satisfaction of the restrictions is reported as increases to net assets without donor restrictions and decreases to net assets with donor restrictions under net assets released from restrictions. If the expiration of restrictions occurs in the same fiscal year as the contribution is received, the contributions are shown as increases in net assets without donor restrictions. Expenses are reported as decreases in net assets without donor restrictions. Promises to give that have both (a) a barrier to be overcome and (b) a right of return or right of release element present are considered conditional, therefore, they are not included as revenue or promises to give until such time as the conditions have been substantially met.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 4—Liquidity and availability of resources

The following represents financial assets at September 30, 2024 and 2023:

Financial assets at year-end:	2024	2023
Cash and cash equivalents	\$ 9,927,974	\$ 21,093,189
Restricted cash	6,317,018	16,126,990
Investments	20,490,404	16,530,847
Restricted investments	20,026,465	15,620,099
Accounts receivable, net	28,258,207	12,185,595
	85,020,068	81,556,720
Less amounts not available to be used for general		
expenditures within one year:		
Restricted cash	(6,317,018)	(16, 126, 990)
Restricted investments	(20,026,465)	(15,620,099)
Restricted by donors for specific purposes	(822,768)	(1,000,148)
Internally designated for debt service	(70,115)	(105,316)
Reimbursements for previously incurred OPTN Contract expenses	(1,625,000)	 (541,667)
Financial assets available to meet general expenditures		
within one year	\$ 56,158,702	\$ 48,162,500

As part of the Organization's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations become due, while also striving to maximize the investment of its available funds. For purposes of analyzing resources available to meet general expenditures over a 12-month period, the Organization considers all expenditures relating to its mission-related activities and supporting services to be general expenditures. Additionally, the Organization operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by the OPTN Contract.

As discussed in Note 2 of the consolidated financial statements, certain financial assets are restricted for use by the OPTN Contract. This results when collection of OPTN registration fees exceed the reimbursable costs incurred at a given point in time by the Organization. The Organization has determined that the use of restricted cash and investments amounts will be for mission-related activities within one year and, accordingly, these amounts are included in financial assets available to meet general expenditures within one year.

In addition to financial assets available to meet general expenditures within one year, the Organization, through its budgeting process, anticipates collecting sufficient registration fees to cover general expenditures that are not covered by reimbursements from the OPTN Contract.

Note 5—Investments

Investments at fair market value as of September 30 consist of the following:

	2024	2023
Investments	\$ 20,490,404	\$ 16,530,847
Restricted investments	20,026,465	15,620,099
Total investments	\$ 40,516,869	\$ 32,150,946

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 5—Investments (continued)

All investments are short-term as of September 30, 2024 and 2023.

Investment income (loss) for the years ended September 30 consisted of the following:

	 2024	2023
Unrealized gains	\$ 3,264,159	\$ 1,744,403
Realized gains (losses)	275,526	(472,621)
Dividends and interest	 943,456	 893,846
	\$ 4,483,141	\$ 2,165,628

Note 6—Accounts receivable

Accounts receivable as shown in the accompanying statement of financial position as of September 30 consists of the following:

	 2024	2023
OPTN registration fees	\$ 8,897,060	\$ 10,118,677
UNOS membership fees	1,406,727	1,158,531
Government contracts	1,625,000	541,667
OPTN voucher fees	15,813,652	-
Unbilled receivables	286,684	-
Other	278,365	421,396
Allowance for credit losses	 (49,281)	(54,676)
	\$ 28,258,207	\$ 12,185,595

Accounts receivable consist of OPTN registration fees, UNOS fees, government contracts, and other receivables and are carried at original amounts. Other receivables primarily consist of amounts due to the Organization from Chorus and solutions revenue. An allowance for credit losses is maintained to provide for the estimated amount of receivables that will not be collected. The allowance is based on customer creditworthiness, historical payment experience, and the age of outstanding receivables. The Organization charges off uncollectible receivables against the allowance when the likelihood of collection is remote. As of September 30, 2024 and 2023, the allowance for doubtful accounts totaled \$49,281 and \$54,676, respectively. Bad debt expense totaled \$48,916 and \$62,576 for the years ended September 30, 2024 and 2023, respectively, and is included in other expenses in the consolidated statement of activities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 7—Property and equipment

Cost and accumulated depreciation as of September 30 are summarized as follows:

	2024			2023
Land	\$	1,113,000	\$	1,113,000
Building		25,445,137		25,237,943
Donor memorial		1,714,512		1,714,512
Computer hardware		20,348,408		19,494,652
Furniture and other equipment		2,491,309		2,372,167
Other fixed assets		553,813		92,360
		51,666,179		50,024,634
Less accumulated depreciation		(33,024,816)		(30,429,225)
Property and equipment, net	\$	18,641,363	\$	19,595,409

Depreciation expense related to property and equipment for the years ended September 30, 2024 and 2023 was \$2,083,125 and \$2,194,642, respectively.

Note 8—Accounts payable and other accrued expenses

As of September 30, accounts payable and other accrued expenses consist of the following:

	 2024	2023		
Trade	\$ 2,459,934	\$	2,899,835	
Other accounts payable	154,902		227,029	
Accrued operating expenses	2,504,612		2,864,306	
Accrued benefit contributions	531		-	
Accrued compensation absences	 3,375,880		3,244,118	
	\$ 8,495,859	\$	9,235,288	

Note 9—Long-term liabilities

In December 2010, the Organization paid off the 2002 bonds payable originally issued in the amount of \$12,000,000, which were used to finance the construction of the corporate headquarters and obtained \$9,720,000 from the issuance of the 2010 bonds payable. Interest is payable on the 2010 bonds payable on the first day of each month. Interest rates were initially determined on the 2010 bonds payable based on a weekly rate as determined by the bank serving as agent for the bond issuance. The Organization has the option to convert the rate to a term rate, as defined, for two or more semi-annual periods, which is determined by the bank such that there is no premium or discount on conversion. The Organization also has the option to convert the rate to a fixed rate to maturity, which is determined by the bank, provided that there is no discount or premium on conversion. At no time may the interest rate exceed 12%. The applicable interest rate as of September 30, 2024 and 2023 was 5.59% and 5.68%, respectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 9—Long-term liabilities (continued)

The Organization incurred \$117,551 and \$163,112 of interest expense for the years ended September 30, 2024 and 2023, respectively. Interest expense is included with other expenses on the consolidated statement of activities. The bonds payable contain restrictive covenants, including the requirement to maintain a minimum debt service coverage ratio and a minimum level of unrestricted liquidity. As of September 30, 2024, management believes the Organization is in compliance with those covenants. Management is reserving cash to meet the required principal and interest payment in accordance with the payment deadlines

Long-term liabilities as of September 30 consist of the following amounts:

	 2024	2023		
2010 bonds	\$ 2,145,000	\$	2,815,000	
Less current maturities	 (690,000)		(670,000)	
Long-term liabilities, less current portion	\$ 1,455,000	\$	2,145,000	

Future maturities on bonds payable at September 30, 2024 are as follows:

Years Ending September 30,	
2025	\$ 690,000
2026	715,000
2027	740,000
	\$ 2,145,000

Note 10—Fair value measurements

The Organization has adopted FASB guidance on fair value measurements. The provisions of the guidance provide a framework for measuring fair value under U.S. GAAP and defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This guidance requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. This guidance also establishes a fair value hierarchy which prioritizes the valuation inputs into three broad levels. Based on the underlying inputs, each fair value measurement in its entirety is reported in one of three levels.

The Organization's assets recorded at fair value on a recurring basis are categorized based on the priority of the inputs used to measure fair value. The inputs used in measuring fair value are categorized into three levels, as follows:

Level 1 – Inputs that are based upon quoted prices for identical instruments traded in active markets.

Level 2 – Inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar investments in markets that are not active, or models based on valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the investment.

Level 3 – Inputs that are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are, therefore, determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Organization has no Level 3 investments.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 10—Fair value measurements (continued)

The asset's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques are used to maximize the use of observable inputs and minimize the use of unobservable inputs. Following is a description of the valuation methodologies used for assets measured at fair value.

Equity Securities and Mutual Funds – Valued at the closing price reported on the active market on which the individual securities are traded.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Organization believes its valuation methods are appropriate and consistent with those of other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. There were no transfers between levels or change in methodology during the years ended September 30, 2024 or 2023.

The following table sets forth by level, within the fair value hierarchy, the Organization's investments at fair value as of September 30, 2024:

Fair Value Using							
	Level 1		Level 2		Level 3		Total
\$	8,727,648	\$	-	\$	-	\$	8,727,648
	29,745,093		-				29,745,093
	38,472,741		-		-		38,472,741
	2,044,128						2,044,128
\$	40,516,869	\$	-	\$	-	\$	40,516,869
		\$ 8,727,648 29,745,093 38,472,741 2,044,128	\$ 8,727,648 \$ 29,745,093 38,472,741 2,044,128	\$ 8,727,648 \$ - 29,745,093 - 38,472,741 - 2,044,128 -	Level 1 Level 2 \$ 8,727,648 \$ - \$ 29,745,093 - 38,472,741 - 2,044,128 -	Level 1 Level 2 Level 3 \$ 8,727,648 \$ - \$ - 29,745,093 38,472,741 - 2,044,128	Level 1 Level 2 Level 3 \$ 8,727,648 \$ - \$ - \$ 29,745,093 38,472,741 2,044,128

The following table sets forth by level, within the fair value hierarchy, the Organization's investments at fair value as of September 30, 2023:

	Fair Value Using					
		Level 1		Level 2	Level 3	Total
Investments:						
Equity securities	\$	8,280,480	\$	-	\$ -	\$ 8,280,480
Mutual funds		21,999,756		-	-	21,999,756
		30,280,236		-	_	30,280,236
Money market, carried at cost		1,870,709		-	 	1,870,709
Total Investments	\$	32,150,946	\$	-	\$ -	\$ 32,150,946

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 11—Employee benefit plans

Retirement benefits for all full-time employees are provided through a qualified defined contribution pension plan. Under the terms of the plan, all employees of the Organization who have completed 1,000 hours of continuous employment earn a year of vesting for plan purposes. All employees are eligible for participation coincident with employment. The Organization contributed an amount equal to 4% of each participant's compensation and matched participant deferrals dollar for dollar up to 6% of employee compensation for the years ended September 30, 2024 and 2023. Employees become fully vested after six years of vesting service, as defined in the plan. Forfeitures serve to reduce the total contribution required of the Organization.

During fiscal year 2023, the Organization began offering a new non-qualified deferred compensation plan that complies with Section 457(f) of the Internal Revenue Code (the "Code"), and the short-term deferral provisions of Section 409A of the Code. The plan is intended to be an unfunded plan maintained primarily for the purpose of providing deferred compensation benefits for a select group of management or highly compensated employees under Sections 201(2), 301(a)(3), and 401(a)(1) of the Employee Retirement Income Security Act of 1974 ("ERISA") and independent contractors.

During fiscal year 2023, the Organization also adopted an incentive plan to provide a means by which certain employees or independent contractors of the Organization may receive performance incentive payments from the Organization. The incentive plan is intended to be a "bonus program" within the meaning of Department of Labor Regulation § 2510.3-2(c) and, therefore, it is intended that the incentive plan not to be subject to ERISA.

Contributions made by the Organization for the years ended September 30, 2024 and 2023 amounted to \$5,609,920 and \$5,021,250, respectively. Contributions are included with employee benefit and payroll taxes on the consolidated statement of activities.

Note 12—Leases

On June 22, 2015, the Organization entered into a lease agreement with Virginia Commonwealth University ("VCU"), which stipulates that VCU is to lease a portion of the Jackson Center from the Organization for a period of ten years and six months, commencing on February 16, 2016. On December 21, 2023, the Organization entered into a lease agreement with FCWS, Inc. ("FCWS"), which stipulates that FCWS is to lease a portion of the Jackson Center from the Organization for a period of sixty-three months, commencing on April 1, 2024.

Rental revenue totaled \$568,480 and \$546,754 for the years ended September 30, 2024 and 2023, respectively, and is included with miscellaneous revenue on the consolidated statement of activities. Rental revenue is recognized on a straight-line basis over the term of the lease agreements which resulted in rent receivable totaling \$154,825 and \$222,880 as of September 30, 2024 and 2023, respectively, which is included with other assets on the consolidated statement of financial position.

Future amounts of rental payments due from VCU and FCWS at September 30, 2024 are as follows:

Years Ending September 30,

2025	\$ 650,583
2026	367,023
2027	46,068
2028	47,450
2029	 48,874
	\$ 1,159,998

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024 (WITH SUMMARIZED COMPARATIVE TOTALS FOR 2023)

Note 13—Commitments and contingencies

DHHS and the General Accounting Office ("GAO") are entitled to review the accounting and other records of the Organization. DHHS is primarily responsible for determining the acceptability of estimated or incurred costs as allowable contract costs under the OPTN Contract. GAO is responsible for determining that procurement actions are made in conformity with applicable laws and regulations. Management is of the opinion that the Organization is in compliance with applicable provisions of the OPTN Contract.

The Organization, in the ordinary course of its business to provide for the fair and equitable distribution of donated organs, is sometimes named as a defendant in litigation involving claims related to its operation of the OPTN. While it is the Organization's policy to handle all claims promptly, efficiently, fairly, and in accordance with the provisions of the OPTN Contract and applicable laws, the Organization may be subjected to a plaintiff's allegations seeking a reimbursement of legal fees. On the basis of information provided by in-house and external counsel and others, the Organization believes there are no contingencies that will materially affect the consolidated financial statements.

The Organization maintains medical, professional, and general liability coverage under various insurance policies.

On March 18, 2021, the Organization entered into an agreement with Accenture. Under the terms of this agreement, Accenture will provide services to the Organization to enhance its ability to provide exceptional services as the OPTN contractor. Under the agreement, the Organization guarantees Accenture a role on the Organization's team for the duration of the remaining OPTN Contract and for the duration of the next two iterations of the OPTN Contract as issued by HHS. The Organization guarantees Accenture a minimum of \$1,500,000 in consulting services for each contract year of the OPTN Contract commencing with fiscal year 2022 under this agreement. The parties agree that for a period of ten years after the effective date of this agreement, Accenture will not at any time or in any manner, use for the benefit of Accenture, or divulge, disclose, or communicate in any manner any information that is proprietary to the Organization. If the terms of this agreements are violated by the Organization, they may be subject to litigation pursuant to terms of the agreements. The agreement is governed by and construed in accordance with the laws of the state of Virginia.

Note 14—Deferred grant revenue

On November 18, 2021, the Organization received notification from the bank that the forgiveness application for the Paycheck Protection Program loan ("PPP") of \$7,250,000 had been accepted by the Small Business Administration ("SBA") and the loan was forgiven. The Organization recognized approximately \$2,600,000 of grant revenue during the year ended September 30, 2022, for amounts attributable to the Organization's specific costs, which was included in miscellaneous revenue on the accompanying consolidated statement of activities. The remaining \$4,650,000 was recognized in miscellaneous revenue during the year ended September 30, 2024, as the remaining portion of the loan is not expected to be reimbursed to HRSA, and UNOS has no recourse to SBA.

Note 15—Subsequent events

Management has evaluated subsequent events for potential recognition and/or disclosure through February 19, 2025, the date the consolidated financial statements were available to be issued and has determined there are no subsequent events to be reported in the accompanying consolidated financial statements.



SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

YEAR ENDED SEPTEMBER 30, 2024

Federal Grantor/Program Title	Federal Assistance Listing Number	Additional Award Identification	Federal Expenditures		
U.S. Department of Health and Human Services - Health Resources and Services Administration:					
Organ Procurement and Transplantation Network	93.U01	HHSH250201900001C	\$ 6,441,705		
			\$ 6,441,705		

NOTES TO THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

YEAR ENDED SEPTEMBER 30, 2024

Note 1—Basis of presentation

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal grant activity of the United Network for Organ Sharing and Subsidiary (the "Organization"). The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards ("Uniform Guidance"). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic consolidated financial statements.


Note 2—Summary of significant accounting policies

Basis of Accounting - Expenditures reported on the Schedule are reported on the accrual basis of accounting.

Indirect Cost Rate – The Organization has elected not to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 3—Subrecipients

There were no amounts of federal expenditures presented in the Schedule that were provided to subrecipients.





Report of Independent Auditor on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Consolidated Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Directors United Network for Organ Sharing and Subsidiary Richmond, Virginia

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of United Network for Organ Sharing and Subsidiary (a nonprofit organization) (the "Organization"), which comprise the consolidated statement of financial position as of September 30, 2024, and the related consolidated statement of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated February 19, 2025.

Report on Internal Control over Consolidated Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Organization's internal control over financial reporting ("internal control") as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Organization's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

21

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Richmond, Virginia

Cherry Bekaert LLP

February 19, 2025



Report of Independent Auditor on Compliance for the Major Federal Program and on Internal Control over Compliance Required by the Uniform Guidance

To the Board of Directors United Network for Organ Sharing and Subsidiary Richmond, Virginia

Report on Compliance for the Major Federal Program

Opinion on the Major Federal Program

We have audited United Network for Organ Sharing and Subsidiary's (the "Organization") compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on the Organization's major federal program for the year ended September 30, 2024. The Organization's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Organization complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended September 30, 2024.

Basis for Opinion on the Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* ("Uniform Guidance"). Our responsibilities under those standards and the Uniform Guidance are further described in the *Auditor's Responsibilities for the Audit of Compliance* section of our report.

We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Organization's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, control and maintenance of effective internal over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to Organization's federal program.

Auditor's Responsibility for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Organization's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Organization's compliance with the requirements of the major federal program as a whole.

cbh.com 23

In performing an audit in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and
 perform audit procedures responsive to those risks. Such procedures include examining, on a test basis,
 evidence regarding the Organization's compliance with the compliance requirements referred to above
 and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Organization's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the Organization's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the *Auditor's Responsibilities for the Audit of Compliance* section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is no suitable for any other purpose.

Richmond, Virginia February 19, 2025

Cherry Bekaert LLP

SCHEDULE OF FINDINGS AND QUESTIONED COSTS

YEAR ENDED SEPTEMBER 30, 2024

Section I—Summary of Auditor's Results

- 1. Type of report issued on whether the basic financial statements are prepared in accordance with U.S. GAAP: **Unmodified**
- 2. Significant deficiencies in internal control over financial reporting: None reported
- 3. Material weaknesses in internal control over financial reporting: No
- 4. Noncompliance, which is material to the financial statements: **No**
- 5. Significant deficiencies in internal control over the major program: None reported
- 6. Material weaknesses in internal control over the major program: No
- 7. The type of report issued on compliance for the major program: Unmodified
- 8. Any audit findings which are required to be reported under Uniform Grant Guidance: No
- 9. The program tested as major program was:

Federal Assistance Listing Number	Name of Federal Program
93.U01	Organ Procurement and Transplantation Network

- 10. Dollar threshold used to distinguish between type A and type B programs: \$750,000
- 11. Auditee qualified as low-risk auditee under Uniform Grant Guidance: Yes

Section II—Findings Relating to the Consolidated Financial Statements Reported in Accordance with Government Auditing Standards:

None reported.

Section III—Findings and Questioned Costs Relating to Federal Awards:

None reported.

Section IV—Status of Prior Year Findings:

A schedule of prior year findings is not necessary since there were no prior year findings.